Fighting
Antibiotic
Failure
ON TWO
FRONTS
Diagnostic
Novel assay provides earlier and faster risk assessment of sepsis and enables targeted treatment.
Therapeutic
Patented pharmaceutical peptide targets currently untreatable biofilm infections. Innovative substrate-independent peptide coatings maintain sterile medical devices and implants.
The crisis: Widespread and deadly*
49 million/year
cases of sepsis
11 million
sepsis deaths a year
100%
incidence of sepsis in COVID deaths
10 to 1000x
more resistant to most antibiotics
0
drugs approved for biofilms
65%
of all infections are biofilms
* Data on file
Investment Highlights
Large Addressable Global Markets
With NO efficient clinical solutions (unmet medical needs)
Novel Technologies
In the early identification of sepsis and treatment of biofilm Infections
Extensive Intellectual Property
Portfolio of both Diagnostics and Therapeutics
Near-term Revenue Models
With multiple corporate partnership targets
Publicly-Listed
For enhanced shareholder liquidity
Experienced Management Team
With proven track records in med-tech and biopharma
Multibillion-dollar opportunity
As sepsis and antibiotic-resistant infections continue to be a severe burden on the healthcare system, Asep Inc. offers excellent investment potential, with a combined market of $179 billion, and robust growth.
$41.9B Global Antibiotic Market CAGR: 3%
Global MRSA Market*
$1.0B
CAGR: 4.4%
Global Device Infection Market
$2.0B
CAGR: 3.6%
Global CRS Market
$2.1B
CAGR: 7.4%
Global Ear Infection Market
$2.8B
CAGR: 5%
Global Bacterial Vaginosis
$4.5B
CAGR: 9%
Global Urinary Tract Infections
$9.5B
CAGR: 3.6%
Global Wound Care Market
$20B
CAGR: 4.1%
$1.0B Global Sepsis Dx CAGR: 8.5%
WEBINARS
Click the link below to view our archived webinars.
Contact
ASEP and its subsidiaries' technologies have not received marketing authorization
and are not currently available for purchase. © 2023 All Rights Reserved